西酞普兰联合奥氮平治疗躯体形式障碍对照研究

目的：探讨西酞普兰联合奥氮平治疗躯体化障碍的临床疗效和安全性。方法将80例躯体化障碍患者随机为两组，每组40例，两组均口服西酞普兰治疗，研究组联合奥氮平治疗，观察6周。于治疗前后采用症状自评量表躯体化因子、汉密顿焦虑量表、汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组各量表评分均较治疗前有显著下降（P＜0．01），同期研究组较对照组下降更显著（P＜0．05或0．01）；治疗6周末研究组有效率为91．4％，对照组为63．6％，研究组显著高于对照组（ P＜0．05）。两组副反应量表评分及不良反应发生率比较差异均无显著性（P＞0．05）。结论西酞普兰联合奥氮平治疗躯体化障碍患者起效快，疗效显著，更有利于提高患者的治疗依从性，显著优于单用西酞普兰治疗。

A control study of citalopram combined with olanzapine in the treatment of somatoform disorders

Objective To explore the efficacy and safety of citalopram combined with olanzapine in the treatment of somatoform disorders （SD） .Methods Eighty SD patients were randomly divided into two groups of 40 ones each ,both groups took orally citalorpam ,and research group was plus olanzapine for 6 weeks .Efficacies were assessed with the somatization factor of Symptom Checklist-90 （SCL-90） ,Hamil-ton Anxiety Scale （HAMA） and Hamilton Depression Scale （HAMD） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before and after treatment .Results All scale’s scores of both groups lowered more significantly after treatment compared with pre-treatment （P〈0 .01） ,so did those in research than in control group in the corresponding period （P〈0 .05 or 0 .01）;effective rate was significantly higher in research than control group at the end of the 6th week （91 .4% vs .63 .6% , P〈0 .05） .There were no significant group differences in the TESS scores and incidences of adverse reac-tions （P〉0 .05） .Conclusion Citaiopram plus olanzapine takes effect more rapidly ,has an evident effect , and is more beneficial to improve patients’ compliance compared with single citaiopram in somatoform dis-orders .